|
1
|
Kyle RA and Rajkumar SV: Multiple myeloma.
N Engl J Med. 351:1860–1873. 2004. View Article : Google Scholar
|
|
2
|
Mitsiades CS, Mitsiades N, Munshi NC and
Anderson KC: Focus on multiple myeloma. Cancer Cell. 6:439–444.
2004. View Article : Google Scholar
|
|
3
|
Bergsagel PL and Kuehl WM: Molecular
pathogenesis and a consequent classification of multiple myeloma. J
Clin Oncol. 23:6333–6338. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Hideshima T, Mitsiades C, Tonon G,
Richardson PG and Anderson KC: Understanding multiple myeloma
pathogenesis in the bone marrow to identify new therapeutic
targets. Nat Rev Cancer. 7:585–598. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Richardson PG, Barlogie B, Berenson J, et
al: A phase 2 study of bortezomib in relapsed, refractory myeloma.
N Engl J Med. 348:2609–2617. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Kumar SK, Rajkumar SV, Dispenzieri A, et
al: Improved survival in multiple myeloma and the impact of novel
therapies. Blood. 111:2516–2520. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Cheriyath V, Jacobs BS and Hussein MA:
Proteasome inhibitors in the clinical setting: benefits and
strategies to overcome multiple myeloma resistance to proteasome
inhibitors. Drugs RD. 8:1–12. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
de Carvalho F, Costa ET, Camargo AA, et
al: Targeting MAGE-C1/CT7 expression increases cell sensitivity to
the proteasome inhibitor bortezomib in multiple myeloma cell lines.
PLoS One. 6:e277072011.PubMed/NCBI
|
|
9
|
Podar K, Gouill SL, Zhang J, et al: A
pivotal role for Mcl-1 in Bortezomib-induced apoptosis. Oncogene.
27:721–731. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Jacobs JJ, Kieboom K, Marino S, DePinho RA
and van Lohuizen M: The oncogene and Polycomb-group gene bmi-1
regulates cell proliferation and senescence through the ink4a
locus. Nature. 397:164–168. 1999. View
Article : Google Scholar : PubMed/NCBI
|
|
11
|
Jacobs JJ, Scheijen B, Voncken JW, Kieboom
K, Berns A and van Lohuizen M: Bmi-1 collaborates with c-Myc in
tumorigenesis by inhibiting c-Myc-induced apoptosis via INK4a/ARF.
Genes Dev. 13:2678–2690. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Leung C, Lingbeek M, Shakhova O, et al:
Bmi1 is essential for cerebellar development and is overexpressed
in human medulloblastomas. Nature. 428:337–341. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Park IK, Qian D, Kiel M, et al: Bmi-1 is
required for maintenance of adult self-renewing haematopoietic stem
cells. Nature. 423:302–305. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Molofsky AV, He S, Bydon M, Morrison SJ
and Pardal R: Bmi-1 promotes neural stem cell self-renewal and
neural development but not mouse growth and survival by repressing
the p16Ink4a and p19Arf senescence pathways. Genes Dev.
19:1432–1437. 2005. View Article : Google Scholar
|
|
15
|
Yang J, Chai L, Liu F, et al: Bmi-1 is a
target gene for SALL4 in hematopoietic and leukemic cells. Proc
Natl Acad Sci USA. 104:10494–10499. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Vonlanthen S, Heighway J, Altermatt HJ, et
al: The bmi-1 oncoprotein is differentially expressed in non-small
cell lung cancer and correlates with INK4A-ARF locus expression. Br
J Cancer. 84:1372–1376. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Larmonie NS, Dik WA, Beverloo HB, van
Wering ER, van Dongen JJ and Langerak AW: BMI1 as oncogenic
candidate in a novel TCRB-associated chromosomal aberration in a
patient with TCRgammadelta+ T-cell acute lymphoblastic leukemia.
Leukemia. 22:1266–1267. 2008. View Article : Google Scholar
|
|
18
|
Choi YJ, Choi YL, Cho EY, et al:
Expression of Bmi-1 protein in tumor tissues is associated with
favorable prognosis in breast cancer patients. Breast Cancer Res
Treat. 113:83–93. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Kim JH, Yoon SY, Kim CN, et al: The Bmi-1
oncoprotein is overexpressed in human colorectal cancer and
correlates with the reduced p16INK4a/p14ARF proteins. Cancer
Letters. 203:217–224. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Song W, Tao K, Li H, et al: Bmi-1 is
related to proliferation, survival and poor prognosis in pancreatic
cancer. Cancer Sci. 101:1754–1760. 2010. View Article : Google Scholar
|
|
21
|
van Leenders GJ, Dukers D, Hessels D, et
al: Polycomb-group oncogenes EZH2, BMI1, and RING1 are
overexpressed in prostate cancer with adverse pathologic and
clinical features. Eur Urol. 52:455–463. 2007.PubMed/NCBI
|
|
22
|
Jagani Z, Wiederschain D, Loo A, et al:
The Polycomb group protein Bmi-1 is essential for the growth of
multiple myeloma cells. Cancer Res. 70:5528–5538. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Crea F, Duhagon Serrat MA, Hurt EM, Thomas
SB, Danesi R and Farrar WL: BMI1 silencing enhances docetaxel
activity and impairs antioxidant response in prostate cancer. Int J
Cancer. 128:1946–1954. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Wang E, Bhattacharyya S, Szabolcs A, et
al: Enhancing chemotherapy response with Bmi-1 silencing in ovarian
cancer. PLoS One. 6:e17918
|
|
25
|
Wu J, Hu D, Yang G, et al: Down-regulation
of BMI-1 cooperates with artemisinin on growth inhibition of
nasopharyngeal carcinoma cells. J Cell Biochem. 112:1938–1948.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Fasano CA, Dimos JT, Ivanova NB, Lowry N,
Lemischka IR and Temple S: shRNA knockdown of Bmi-1 reveals a
critical role for p21-Rb pathway in NSC self-renewal during
development. Cell Stem Cell. 1:87–99. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Huang BB, Gao QM, Liang W, Xiu B, Zhang WJ
and Liang AB: Down-regulation of SENP1 expression increases
apoptosis of Burkitt lymphoma cells. Asian Pac J Cancer Prev.
13:2045–2049. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Fonseca R, Barlogie B, Bataille R, et al:
Genetics and cytogenetics of multiple myeloma: a workshop report.
Cancer Res. 64:1546–1558. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Briani C, Berno T, Campagnolo M and
Zambello R: Lenalidomide for bortezomib-resistant multiple myeloma.
Nat Rev Clin Oncol. 7: View Article : Google Scholar : 2010. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Hideshima T, Bradner JE, Wong J, et al:
Small-molecule inhibition of proteasome and aggresome function
induces synergistic antitumor activity in multiple myeloma. Proc
Natl Acad Sci USA. 102:8567–8572. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Liu L, Andrews LG and Tollefsbol TO: Loss
of the human polycomb group protein BMI1 promotes cancer-specific
cell death. Oncogene. 25:4370–4375. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Wang H, Pan K, Zhang HK, et al: Increased
polycomb-group oncogene Bmi-1 expression correlates with poor
prognosis in hepatocellular carcinoma. J Cancer Res and Clin Oncol.
134:535–541. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Mihara K, Chowdhury M, Nakaju N, et al:
Bmi-1 is useful as a novel molecular marker for predicting
progression of myelodysplastic syndrome and patient prognosis.
Blood. 107:305–308. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Yu J, Tiwari S, Steiner P and Zhang L:
Differential apoptotic response to the proteasome inhibitor
Bortezomib [VELCADE, PS-341] in Bax-deficient and p21-deficient
colon cancer cells. Cancer Biol Ther. 2:694–699. 2003.
|
|
35
|
An B, Goldfarb RH, Siman R and Dou QP:
Novel dipeptidyl proteasome inhibitors overcome Bcl-2 protective
function and selectively accumulate the cyclin-dependent kinase
inhibitor p27 and induce apoptosis in transformed, but not normal,
human fibroblasts. Cell Death Differ. 5:1062–1075. 1998. View Article : Google Scholar
|
|
36
|
Lazzarini R, Moretti S, Orecchia S, Betta
PG, Procopio A and Catalano A: Enhanced antitumor therapy by
inhibition of p21waf1 in human malignant mesothelioma. Clin Cancer
Res. 14:5099–5107. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Gross A, McDonnell JM and Korsmeyer SJ:
BCL-2 family members and the mitochondria in apoptosis. Genes Dev.
13:1899–1911. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Herrmann JL, Briones F Jr, Brisbay S,
Logothetis CJ and McDonnell TJ: Prostate carcinoma cell death
resulting from inhibition of proteasome activity is independent of
functional Bcl-2 and p53. Oncogene. 17:2889–2899. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Tan TT, Degenhardt K, Nelson DA, et al:
Key roles of BIM-driven apoptosis in epithelial tumors and rational
chemotherapy. Cancer Cell. 7:227–238. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
McConkey DJ and Zhu K: Mechanisms of
proteasome inhibitor action and resistance in cancer. Drug Resist
Updat. 11:164–179. 2008. View Article : Google Scholar : PubMed/NCBI
|
